cyrilzakka/clinical-trials huggingface dataset:
Intrauterine Lidocaine for Laminaria

This is a study to investigate whether instilling a small amount of liquid lidocaine into the uterus will decrease pain felt by women during laminaria insertions done for cervical dilation prior to second trimester abortion.

The investigators hypothesize that women who receive intrauterine lidocaine in addition to a paracervical block will experience less pain than women who receive only a paracervical block.


Eligibility Criteria:
Inclusion Criteria:

* Can sign informed consent
* Healthy pregnant females
* Weight over 45kg
* Seeking abortion by dilation and evacuation in the second trimester of pregnancy
* Gestational age 14-24 weeks confirmed by clinic ultrasound

Exclusion Criteria:

* Known allergy or previous reaction to lidocaine, bupivicaine or other anesthetic agent
* Known allergy or previous reaction to ibuprofen or other NSAID
Concomitant Versus Delayed Cholecystectomy for Management of Obesity With Gallstone

in this study we compare the results of concomitant cholecystectomy with bariatric surgery versus delayed cholecystectomy for management of gallstone in obese patients

in this study we compare the results of concomitant cholecystectomy with bariatric surgery versus delayed cholecystectomy for management of gallstone in obese patients. patients will be divided into 2 group: group1, will be operated by the bariatric surgery and cholecystectomy in the same session. group 2 will be operated by cholecystectomy at least 6 months after bariatric surgery or whenever develop complications

Eligibility Criteria:
Inclusion Criteria:

* BMI \> 35
* presence of gallstone
* fit for laparoscopic surgery

Exclusion Criteria:

* BMI \< 35
* unfit for surgery
* refuse to share in the study
Comparative Effects of Nerve Gliding Exercises and Conventional Grip Strength Exercises in Batters.

Cricket is transformed over the years and dynamic of batting has changed. Gone are the days, when batters used to play the game with defensive mindset. Maintaining higher striker rate and arsenal of power hitting is the epitome of stroke play in limited overs cricket.This study will compare the effects of the nerve gliding exercises and conventional grip strength exercises on handgrip strength, range of motion and performance of cricket batters.

It will be a randomized clinical trial where non-probability convenience sampling will be used to recruit participants aged 18 to 35 years from various cricket academies in Lahore.

Cricket is transformed over the years and dynamic of batting has changed. Gone are the days, when batters used to play the game with defensive mindset. Maintaining higher striker rate and arsenal of power hitting is the epitome of stroke play in limited overs cricket. After modernization of the game, several exercises are adapted to enhance the hitting capability of batsmen with conventional grip strength training but the effectiveness of nerve gliding exercises on handgrip strength is not utilized in cricketing population effectively as compared to tennis and squash players, where it improves the efficiency of wrist mobility in efficient stroke play. This study will compare the effects of the nerve gliding exercises and conventional grip strength exercises on handgrip strength, range of motion and performance of cricket batters. It will be a randomized clinical trial where non-probability convenience sampling will be used to recruit participants aged 18 to 35 years from various cricket academies in Lahore.

Participants will be randomized through lottery method and allocated into two groups. Group A (n=20) participants will receive nerve gliding exercises intervention, while Group B (n=20) will receive conventional grip strength exercises intervention. The Adjustable Hand Dynamometer for Grip Strength, Goniometer for Range of motion while Batting Tee Test for performance will be outcome measure tools. Data will be analyzed by SPSS version 26. The normality of the data will be conducted through the Shapiro-Wilk test; for between-group analysis, an independent t-test or Mann-Whitney will be conducted. Similarly, a paired t-test or Wilcoxon Rank test will be conducted for within-group analysis.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 to 35 years

  * Batsmen
  * Doing net practices more than 4 days per week for at least 3 months.
  * Right hand grip strength (men) 42.9-46.4, Left hand grip strength (men) 42.042.2.

Exclusion Criteria:

* Non-Athletic Population

  * Upper extremity peripheral neuropathies.
  * Tennis/Golfer epicondylitis. Cervical disc herniation.
  * Overuse injuries of the shoulder joint that may affect handgrip strength.
  * Having any neurological or orthopaedical problem related to upper extremity.
Dysphagia Symptom Severity and Quality of Life

The aim of the study is to investigate the relationship between dysphagia symptom severity and quality of life of the patients with neurogenic dysphagia.

The dysphagia related quality of life and perceived dysphagia symptom severity by patients will be used as a complementary information on oropharyngeal dysphagia. Thus, the aim of the study is to investigate the relationship between dysphagia symptom severity and quality of life of the patients with neurogenic dysphagia.

Eligibility Criteria:
Inclusion Criteria:

* Willing to participate in the study
* Being over the age of 20
* Normal cognitive function
* Suffering from dysphagia at least one month

Exclusion Criteria:

* Being under the age of 20 and above 65 years.
* Abnormal cognitive function
* Clinically unstable neurological disease
A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

The primary objective of the study is to estimate the treatment effect of PDA001 (evaluating 3 different PDA001 dosings) versus placebo in subjects with moderate-to-severe Crohn's Disease. The secondary objective of the study is to assess the safety and tolerability of PDA001 versus placebo in the above-mentioned patient population.


Eligibility Criteria:
Inclusion Criteria:

1. Males and females ages 18-75 years
2. Understand and voluntarily sign an informed consent
3. Able to adhere to the study visit schedule and other protocol requirements
4. Minimum weight of 50 kg
5. A female of childbearing potential (FCBP)† must have a negative urine pregnancy test at screening (Visit 1) and immediately prior to all doses of IP. In addition, sexually active FCBP must agree to use two of the adequate forms of contraception methods for the duration of the study and the follow-up period. A FCBP must agree to have pregnancy tests at least every 4 weeks during the study. Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP for the duration of the study and the follow-up period.
6. Subject must have inflammatory CD 6 months prior to treatment and have confirmation of ongoing disease activity by colonoscopy or (other method) at screening
7. Subject must have a CDAI score \> 220 and \< 450 as assessed between Visit 1 and Visit 2
8. The Subject must have failed, i.e., had an inadequate response or lost response (recurrence of symptoms) to an agent, or documented intolerance to an agent at any time

Exclusion Criteria:

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study

A female of childbearing potential is a sexually mature woman who:

1. has not undergone a hysterectomy or bilateral oophorectomy
2. has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Outcomes Data of Adipose Stem Cells to Treat Rheumatoid Arthritis

The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on pain and functionality in people with rheumatoid arthritis (RA). SVF contains multiple cellular components, including stem cells, with both regenerative and anti-inflammatory properties. This therapy has shown promise for ameliorating the symptoms of RA. This study is designed to evaluate changes in pain and functionality in individuals with RA for up to 12 months following SVF treatment.


Eligibility Criteria:
Inclusion Criteria:

* Subjects diagnosed with rheumatoid arthritis
* Subjects scheduled for a stem cell/SVF treatment
* Subjects willing and able to sign informed consent
* Subjects willing and able to perform follow-up interviews and surveys

Exclusion Criteria:

* Subjects with addition major health condition/disease diagnoses
* Subjects that are pregnant or breastfeeding
A Therapeutic Workplace for Alcohol Dependence

The purpose of this study is to determine whether the Therapeutic Workplace is effective in increasing and maintaining long-term drug abstinence in homeless, alcohol dependent adults.

Few populations are beset with the constellation of economic, social and health problems that afflict homeless individuals. At the heart of much of this misfortune are staggering rates of alcoholism and drug addiction. While it is not clear whether substance abuse is a cause, consequence, or simply a correlate of homelessness, there is no question that substance abuse is among the most common and most serious problems facing the homeless. Given their unique set of serious and chronic problems, the Institute of Medicine has identified the homeless as a group of people in need of specialized substance abuse interventions. Prior research has shown that the Therapeutic Workplace intervention is effective in the treatment of chronically unemployed heroin and cocaine dependent individuals. The intervention integrates abstinence reinforcement contingencies of proven efficacy into a model supported work program. Under this intervention, patients are paid to perform data entry jobs in the Therapeutic Workplace. Those lacking needed skills are given intensive training in basic academic and job skills. To reinforce abstinence from alcohol and drugs, patients are required to provide an alcohol-free breath sample and drug-free urine sample to gain entrance to the workplace each day. In this way, patients can work and earn salary only when they abstain from alcohol and drugs. Patients are paid in vouchers instead of cash to reduce the chance they will use their earnings to purchase alcohol or drugs.

A randomized trial was conducted to evaluate the efficacy of this intervention in homeless, alcohol-dependent adults who completed an inpatient alcohol detoxification. After the detoxification, 124 participants were invited to attend the workplace for 6 months. They were randomly assigned to one of three groups that differed in the requirements for voucher reinforcement. One group received the full therapeutic workplace intervention in which vouchers were contingent on both abstinence and work (Abstinence and Work group). A second group was paid for work, but did not have to provide an alcohol-free breath sample or drug-free urine sample to gain access to the workplace; their vouchers were contingent on work only (Work-Only group). A third group was invited to attend the therapeutic workplace but received no vouchers for work performed or abstinence achieved during treatment (No Voucher group).

Eligibility Criteria:
Inclusion Criteria:

* meet DSM IV criteria for alcohol dependence
* are homeless in that they lack a fixed nighttime residence
* are unemployed
* are at least 18 years old

Exclusion Criteria:

* are currently physically dependent on opioids
* are considered in imminent risk of suicide
* have a psychiatric disorder that is likely to result in behaviors that could disrupt the workplace functioning or limit their ability to provide informed consent
* are physically unable to perform typing or keypad entry
Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)

1. Sustained low efficiency daily hemodiafiltration(SLEDD-f) is a kind of renal replacement therapy with high-flux dialyser membrane (helixone).
2. The pore size of helixone is larger than most antibiotics, and vancomycin is supposed to be removed during dialysis.
3. Our study wants to find the amount of vancomycin removed during SLEDD-f, and try to find the most appropriate dose regimen for this kind of patients.

Vancomycin is the most important antibiotic in the treatment of resistant G(+) bacteria infections. Close monitor of serum level is important to ensure its safety and effectiveness. So far there is not enough data to support the optimal dose regimen of vancomycin in patients on SLEDD-f. In this study, we draw blood levels between 2 doses of vancomycin to determine the pharmacokinetic parameters of vancomycin and fraction removed by SLEDD-f so as to determine the most appropriate dose regimen.

Eligibility Criteria:
Inclusion Criteria:

* Acute renal failure of any cause
* Use SLEDD-f as renal replacement therapy
* Priscribe vancomycin for a known or suspected infection

Exclusion Criteria:

* None
Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.

The purpose of this study is to evaluate thyroid nodule's volume, structure and vascularisation changes following HIFU therapy assessed by ultrasonography

HIFU treatment will be performed under conscious sedation under the supervision / responsibilities of an anesthetist.

A maximum of 2 HIFU sessions per nodule will be performed per patient. The decision to retreat the patient will be taken at 1 month post-HIFU or later.

Follow-up after HIFU treatment

D1 after HIFU session:

* Indirect laryngoscopy to check vocal cord mobility.

D7 after HIFU session

* Clinical examination (skin, local symptoms, oedema, voice....),
* Ultrasonography and Power Doppler,

M1 after HIFU session

* Clinical examination (skin, local symptoms, oedema, voice....),
* Ultrasonography and Power Doppler,

M3 after HIFU session

* Clinical examination (skin, local symptoms, oedema, voice....),
* Ultrasonography and Power Doppler Decision for an additional HIFU course to improve volume reduction.

In case of a second HIFU session D7b, M1b and M3b, M6b, M9b, M12b, M18b, M24b and M36b will be performed

M6 after last HIFU session

* Clinical examination (skin, local symptoms, oedema, voice....),
* Ultrasonography and Power Doppler
* TSH
* Free T4
* Antithyroid peroxidase antibodies
* Calcemia and PTH (in case of bilateral treatment or in case previous thyroid surgery)

M9 after HIFU session

* Clinical examination (skin, local symptoms, oedema, voice....),
* Ultrasonography and Power Doppler

M12 after last HIFU session

* Clinical examination (skin, local symptoms, oedema, voice....),
* Ultrasonography and Power Doppler
* TSH
* Free T4
* Antithyroid peroxidase antibodies
* Calcemia and PTH (in case of bilateral treatment or in case previous thyroid surgery)

M18, M24, M36 after HIFU session

* Clinical examination (skin, local symptoms, oedema, voice....),
* Ultrasonography and Power Doppler

Eligibility Criteria:
Inclusion Criteria:

* Male or female patient 18 years or older.
* Patient presenting with at least one thyroid nodule with no signs of malignancy:

  1. Non suspect clinically and at ultrasonography imaging
  2. Benign cytological diagnosis at FNAB from the last 6 months
  3. Normal serum calcitonin
  4. No history of neck irradiation
* Normal TSH.
* Targeted nodule accessible and eligible to HIFU
* Absence of abnormal vocal cord mobility at laryngoscopy.
* Nodule diameter ≥ 10mm measured by ultrasound.
* Composition of the targeted nodule(s) : no more than 30% cystic

Exclusion Criteria:

* Head and/or neck disease that prevents hyperextension of neck.
* Known history of thyroid cancer or other neoplasias in the neck region.
* History of neck irradiation.
* Macrocalcification inducing a shadow in the thyroid significant enough to preclude the HIFU treatment
* Posterior position of the nodule if the thickness of the nodule is \<15mm
* Pregnant or lactating woman
* Any contraindication to IV neurolept analgesia.
Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy. The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient. Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis. GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH. After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation test, which is conducive to the formulation of the following treatment. GnRH pump can pulse subcutaneous injection of gonadorelin, which can be used as the extended provocation test.


Eligibility Criteria:
Inclusion Criteria:

* patients with HH after surgery of the saddle area
* sufficient therapy of the hypothalamic-pituitary-adrenal(HPA) and hypothalamic-pituitary-thyroid(HPT) axis

Exclusion Criteria:

* contradictions to gonadorelin
* androgen-dependent prostate cancer
* on the therapy of human chorionic gonadotropin(HCG) or testosterone
Intense Therapeutic Ultrasound (ITU) to Treat Plantar Fasciitis

It was previously hypothesized that patients receiving Intense Therapeutic Ultrasound (ITU) in addition to the standard of care would have a more rapid resolution of pain, faster return to activities, and a decrease in intra- and perifascial lesions.

Intense Therapeutic Ultrasound (ITU) is an established ultrasound-based therapy in which sound waves are concentrated and focused into a well-defined specific area of musculoskeletal tissue. Previous researches hipothesize that the application of ITU improve and accelerate healing in patients with chronic plantar fasciitis.

Eligibility Criteria:
Inclusion Criteria:

* Both sex patients.
* Plantar fasciitis diagnosis: pain during walking during the first steps in the morning; pain due to palpation of plantar fasciia insertion.
* Chronic pain of at least 6 month.
* Longitudinal thickness of the plantar fasciia more than 4 millimeters.
* No previous surgery in the plantar fasciia.
* No previous application of alternative treatments such us shock waves or injections (last ninety days)

Exclusion Criteria:

* Platelet count disorder or anticoagulation therapy.
* Anti-inflammatories usual treatment for the treatment of plantar fasciitis.
* Diabetic foot syndrome.
* Presence of metabolic disease such us: hypertension, hiper or hipothyroidism.
* Pregnancy or breastfeeding.
* Previous treatment with fluoroquinolones antibiotic.
* Bilateral plantar fasciitis.
* Diagnosed Autoimmune disesase.
* Morphofunctional disorders in the foot and ankle.
* Diagnosed fibromyalgia.
* Heel disestesy.
Device Based Therapy in Hypertension Trial

The purpose of this study is to demonstrate the safety and efficacy of the Rheos Baroreflex Hypertension Therapy System in patients with refractory hypertension.

The DEBuT-HT trial will investigate the safety and efficacy of Rheos Baroreflex Hypertension Therapy(TM) in patients with refractory hypertension despite full pharmacologic therapy. Enrolled patients will be carefully assessed prior to receiving a permanently implanted Rheos System. Once the system is implanted, these patients will be followed closely for 1 month to establish baseline information. The Rheos System will be programmed "ON" at the 1 month follow-up and incrementally increased at 2 and 3-month follow-up evaluations. An assessment of safety and efficacy will be made at the 4-month follow-up. Enrolled patients will be followed annually thereafter.

Eligibility Criteria:
Inclusion Criteria:

* Be at least 21 years of age.
* Have been assessed to have bilateral carotid bifurcations located at or below C3 - C4.
* Have blood pressure greater than or equal to 160 mmHg systolic and/or greater than or equal to 90 mmHg diastolic despite at least two months of full therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic.
* Must be certified by the investigator as compliant to taking full doses of medications.
* Have signed an approved informed consent form for participation in this study.

Exclusion Criteria:

* Have been diagnosed with:

  * Baroreflex failure or significant orthostatic hypotension
  * Cardiac brady arrhythmias or chronic atrial fibrillation
* Have carotid atherosclerosis determined by ultrasound or angiographic evaluation with a stenosis of greater than 50%.
* Have prior surgery or radiation in either carotid sinus region
* Currently have implanted electrical medical devices such as cardiac pacing, defibrillation or neurologic stimulation systems.
* Are pregnant or contemplating pregnancy during the 4-month follow-up period.
* Are on dialysis
* Have hypertension secondary to a treatable cause
* Have clinically significant cardiac valvular disease
* Are unable to comply with protocol requirements.
* Are unlikely to survive the protocol follow-up period
* Are enrolled in another concurrent clinical trial
Natural History of Infantile Neuroaxonal Dystrophy

This is a retrospective and cross-sectional review of the natural history of INAD.

After obtaining informed consent, the study participants' relevant medical records will be collected and reviewed. If needed, a telephone or video conference will be scheduled with the patient's family to confirm and clarify information in the medical record. Deceased patients may be eligible for inclusion the retrospective registry if medical records are sufficient and indicate eligibility. Data will be pooled and presented in aggregate, without identification of individual subjects.

Eligibility Criteria:
Inclusion Criteria:

* Male or female 18 months to 10 years of age
* Medical history consistent with the symptoms of classic INAD (onset of symptoms between the ages of 6 months and 3 years)
* Homozygous for PLA2G6 deficiency (variant alleles may be mixed heterozygotes)
* Signed informed consent form (ICF) prior to entry into the registry

Exclusion Criteria:

* Diagnosis of atypical NAD (ANAD)
* Unwilling or unable to allow medical record review